Contraindicated (1)bortezomib will raise the stage or outcome of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or reasonable CYP2C19 inhibitors may enhance mavacamten systemic publicity, leading to heart failure due to systolic dysfunction. Inquire your health practitioner if you have questions on different types of start control that https://trevoryslct.idblogmaker.com/26509717/cp-866087-fundamentals-explained